GH Research
🇮🇪Ireland
- Country
- 🇮🇪Ireland
- Ownership
- Public
- Established
- 2018-01-01
- Employees
- 49
- Market Cap
- $588.9M
- Website
- http://www.ghres.com
- Introduction
GH Research Plc operates as a holding company, which engages in the provision of biopharmaceutical products and services. It develops therapeutic products for patients of psychiatric and neurological disorders. The firm develops novel and proprietary 5-Methoxy-N and N-Dimethyltryptamine, or 5-MeO-DMT, therapies. The company was founded by Theis Terwey, Florian Sch?nharting, and Magnus Halle in 2018 and is headquartered in Dublin, Ireland.
GH Research Announces Successful Outcome of the Phase 2 Clinical Trial for GH001 in Treating Treatment-Resistant Depression
GH Research PLC reported a Phase 2 clinical trial success for GH001 in treating treatment-resistant depression, with 87.5% of patients in remission by day 7. The trial also showed significant MADRS score improvements and no serious adverse events, supporting GH001's safety and efficacy profile.
© Copyright 2025. All Rights Reserved by MedPath